Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Annexon Biosciences

< Previous 1 2 Next >
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Biosciences to Present at the Jefferies London Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Biosciences to Participate in Upcoming September Investor Conferences
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual Meeting
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Announces Pricing of $125 Million Underwritten Public Offering
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Announces Proposed Public Offering of Common Stock
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Biosciences to Present at the Bank of America Health Care Conference
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.